pmc logo imageJournal ListSearchpmc logo image
Logo of canfamphysJournal URL: redirect3.cgi?&&auth=0HeMENuV3iijTdDoACDIY1xqxM968mX-NKfQTdAFi&reftype=publisher&artid=2146197&article-id=2146197&iid=157259&issue-id=157259&jid=303&journal-id=303&FROM=Article|Banner&TO=Publisher|Other|N%2FA&rendering-type=normal&&http://www.cfpc.ca/cfp/
Can Fam Physician. 1996 January; 42: 62–71.
PMCID: PMC2146197
Les contraceptifs à base de désogestrel: la pilule parfaite pour les lipides?
Desogestrel contraceptives: the perfect pill for lipids?
L. Laurendeau
Université de Montréal.
Abstract
OBJECTIVES: A review of clinical trials of changes in lipoprotein composition in women receiving oral contraceptives containing desogestrel; a comparison of the trials' findings and a discussion of their clinical significance. METHODOLOGY: Using MEDLINE, we searched for articles published in English and French between 1982 and 1993 and reviewed the references they contained. The criteria for inclusion were: the basic design of the study (randomised prospective or with crossover), the age of the women, the use of a monophasic oral contraceptive containing desogestrel, the length of the trial (minimum 3 months), and comparison of patients' lipoprotein composition before and after treatment. RESULTS: Among the 17 articles identified, eight studies that met the criteria were reviewed. Their findings all pointed in the same general direction, but contained several major biases, making interpretation difficult. Overall, oral contraceptives containing desogestrel tended to have a beneficial effect; however, there was no significant effect on total cholesterol, a slight tendency toward an increase in HDL, and a slight tendency toward a decrease in LDL. An increase in TG was the only constant and significant change. CONCLUSION: Oral contraceptives containing desogestrel appear to have a favourable effect on HDL and LDL; however, their effect is not significant. It is, therefore, too early to conclude that they offer protection against coronary heart disease.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Mann, JI; Vessey, MP; Thorogood, M; Doll, SR. Myocardial infarction in young women with special reference to oral contraceptive practice. Br Med J. 1975 May 3;2(5965):241–245. [PubMed]
  • Mann, JI; Inman, WH. Oral contraceptives and death from myocardial infarction. Br Med J. 1975 May 3;2(5965):245–248. [PubMed]
  • Vessey, MP; McPherson, K; Johnson, B. Mortality among women participating in the Oxford/Family Planning Association contraceptive study. Lancet. 1977 Oct 8;2(8041):731–733. [PubMed]
  • Shapiro, S; Slone, D; Rosenberg, L; Kaufman, DW; Stolley, PD; Miettinen, OS. Oral-contraceptive use in relation to myocardial infarction. Lancet. 1979 Apr 7;1(8119):743–747. [PubMed]
  • Mann, JI; Inman, WH; Thorogood, M. Oral contraceptive use in older women and fatal myocardial infarction. Br Med J. 1976 Aug 21;2(6033):445–447. [PubMed]
  • Rosenberg, L; Hennekens, CH; Rosner, B; Belanger, C; Rothman, KJ; Speizer, FE. Oral contraceptive use in relation to nonfatal myocardial infarction. Am J Epidemiol. 1980 Jan;111(1):59–66. [PubMed]
  • Ory, HW. Association between oral contraceptives and myocardial infarction. A review. JAMA. 1977 Jun 13;237(24):2619–2622. [PubMed]
  • Hirvonen, E; Idänpään-Heikkilä, J. Cardiovascular death among women under 40 years of age using low-estrogen oral contraceptives and intrauterine devices in Finland from 1975 to 1984. Am J Obstet Gynecol. 1990 Jul;163(1 Pt 2):281–284. [PubMed]
  • Stampfer, MJ; Willett, WC; Colditz, GA; Speizer, FE; Hennekens, CH. Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study. Am J Obstet Gynecol. 1990 Jul;163(1 Pt 2):285–291. [PubMed]
  • Thorneycroft, IH. Oral contraceptives and myocardial infarction. Am J Obstet Gynecol. 1990 Oct;163(4 Pt 2):1393–1397. [PubMed]
  • Fowkes, FG; Fulton, PM. Critical appraisal of published research: introductory guidelines. BMJ. 1991 May 11;302(6785):1136–1140. [PubMed]
  • Kauppinen-Mäkelin, R; Kuusi, T; Ylikorkala, O; Tikkanen, MJ. Contraceptives containing desogestrel or levonorgestrel have different effects on serum lipoproteins and post-heparin plasma lipase activities. Clin Endocrinol (Oxf). 1992 Feb;36(2):203–209. [PubMed]
  • Petersen, KR; Skouby, SO; Pedersen, RG. Desogestrel and gestodene in oral contraceptives: 12 months' assessment of carbohydrate and lipoprotein metabolism. Obstet Gynecol. 1991 Oct;78(4):666–672. [PubMed]
  • Gevers Leuven, JA; Dersjant-Roorda, MC; Helmerhorst, FM; de Boer, R; Neymeyer-Leloux, A; Havekes, L. Estrogenic effect of gestodene- or desogestrel-containing oral contraceptives on lipoprotein metabolism. Am J Obstet Gynecol. 1990 Jul;163(1 Pt 2):358–362. [PubMed]
  • Kloosterboer, HJ; van Wayjen, RG; van den Ende, A. Comparative effects of monophasic desogestrel plus ethinyloestradiol and triphasic levonorgestrel plus ethinyloestradiol on lipid metabolism. Contraception. 1986 Aug;34(2):135–144. [PubMed]
  • Gaspard, UJ; Buret, J; Gillain, D; Romus, MA; Lambotte, R. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. Contraception. 1985 Apr;31(4):395–408. [PubMed]
  • Bergink, EW; Kloosterboer, HJ; Lund, L; Nummi, S. Effects of levonorgestrel and desogestrel in low-dose oral contraceptive combinations on serum lipids, apolipoproteins A-I and B and glycosylated proteins. Contraception. 1984 Jul;30(1):61–72. [PubMed]
  • Samsioe, G. Comparative effects of the oral contraceptive combinations 0.150 mg desogestrel + 0.030 mg ethinyloestradiol and 0.150 mg levonorgestrel + 0.030 mg ethinyloestradiol on lipid and lipoprotein metabolism in healthy female volunteers. Contraception. 1982 May;25(5):487–503. [PubMed]
  • Krauss, RM; Roy, S; Mishell, DR, Jr; Casagrande, J; Pike, MC. Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: differential changes in high-density lipoprotein subclasses. Am J Obstet Gynecol. 1983 Feb 15;145(4):446–452. [PubMed]
  • Godsland, IF; Crook, D; Simpson, R; Proudler, T; Felton, C; Lees, B; Anyaoku, V; Devenport, M; Wynn, V. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 1990 Nov 15;323(20):1375–1381. [PubMed]
  • Krauss, RM. Regulation of high density lipoprotein levels. Med Clin North Am. 1982 Mar;66(2):403–430. [PubMed]
  • Schlierf, G; Arab, L; Oster, P. Influence of diet on high-density lipoproteins. Am J Cardiol. 1983 Aug 22;52(4):17B–19B. [PubMed]
  • Sackett, DL. Bias in analytic research. J Chronic Dis. 1979;32(1-2):51–63. [PubMed]
  • Gordon, T; Castelli, WP; Hjortland, MC; Kannel, WB; Dawber, TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977 May;62(5):707–714. [PubMed]
  • Kannel, WB; Castelli, WP; Gordon, T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med. 1979 Jan;90(1):85–91. [PubMed]
  • Hulley, SB; Rosenman, RH; Bawol, RD; Brand, RJ. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med. 1980 Jun 19;302(25):1383–1389. [PubMed]